1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AstraZeneca Believes Size Matters In Amyloidosis

 
• By Elizabeth Cairns

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.    

AstraZeneca stand at ASCO 2024

Following the presentation of detailed Phase III data last week, Alnylam Pharmaceuticals Inc.’s Amvuttra seems likely to become the first gene silencer approved for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). But perhaps not the last: Ionis Pharmaceuticals, Inc. and AstraZeneca PLC are awaiting pivotal data on Wainua (eplontersen) in the disease, and their decision to enroll huge numbers of patients could give their product an edge.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

More from Leadership

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 
• By Jessica Merrill

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.

GSK: Blenrep’s Return Is Just The Start Of Our Oncology Renaissance

 
• By Andrew McConaghie

GSK’s antibody-drug conjugate looks set for a blockbuster future in multiple myeloma after an approval in the UK, and the company’s head of oncology says it is already planning for the next generation of therapies.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.